Oral administration of glycine and polyamine receptor antagonists blocks ethanol withdrawal seizures.
Cessation of chronic administration of orally administered large amounts of ethanol for 7 days resulted in a markedly increased frequency of audiogenic seizures in Sprague-Dawley rats. Oral administration of the novel glycine receptor antagonist, L-701,324, produced a dose-dependent (2.5 and 5.0 mg/kg; -30 min) inhibition of ethanol withdrawal signs when measured about 12 h after withdrawal of the ethanol treatment. Similarly, using the same experimental paradigm, oral administration of the specific polyamine receptor antagonist, eliprodil, caused a dose-related (2.0 and 5.0 mg/kg; -30 min) inhibition of ethanol withdrawal-induced audiogenic seizure activity. The inhibition of ethanol withdrawal seizures produced by L-701,324 and eliprodil, respectively, was obtained at doses which by themselves did not change the locomotor activity in naive Sprague-Dawley rats. The findings that L-701,324 and eliprodil are potent inhibitors of seizure activity induced by cessation of chronic ethanol administration and the fact that they, in contrast to currently available NMDA receptor antagonists, do not produce psychotomimetic and/or sedative effects, suggest that these drugs may represent a new class of therapeutically useful pharmacological agents for the treatment of ethanol withdrawal seizures. Furthermore, since there is evidence that eliprodil produces its pharmacological actions through a specific inhibition of NMDAR1 and/or NMDAR2B subunits, these data may indicate that certain NMDA receptor subunits may be of particular importance for the mediation of seizure activity following the discontinuation of chronic ethanol exposure.
Kotlinska
J
J
Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden.
Liljequist
S
S
D000161:Acoustic Stimulation; D000284:Administration, Oral; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D002492:Central Nervous System Depressants / Q000009:adverse effects*; D016291:Dizocilpine Maleate / Q000494:pharmacology; D000431:Ethanol / Q000009:adverse effects*; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D010880:Piperidines / Q000627:therapeutic use*; D015363:Quinolones / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012640:Seizures / Q000139:chemically induced / Q000517:prevention & control*; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control*
D000927:Anticonvulsants; D002492:Central Nervous System Depressants; D018691:Excitatory Amino Acid Antagonists; D010880:Piperidines; D015363:Quinolones; D000431:Ethanol; D016291:Dizocilpine Maleate; C094635:L 701324; C058083:eliprodil